Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT)
Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...
Zacks Investment Research on MSN12d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Fierce Biotech13d
Immunovant won't seek approval for autoimmune drug despite phase 3 win
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
BioSpace13d
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
Immunovant's muscle drug meets main goal, shares gain on new drug promise
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
Leerink Partners Reaffirms Their Buy Rating on Immunovant (IMVT)
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...
Immunovant announces results from Phase 3 study of batoclimab in MG
Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...